ABOUT REFORM BIOLOGICS
At ReForm, our vision is to improve the lives of fragile patients by optimizing the delivery of their essential biologic medicines. Fragile patients include children and the elderly, as well as those suffering from neurological conditions and other debilitating diseases. With easier delivery of vital treatments, patients can experience less disruption and less pain, facilitating overall better adherence to therapeutic guidelines with better outcomes.
Our mission is to improve biologic formulations by incorporating our proprietary, patented technology to enhance patients’ lives, particularly for fragile populations such as children and the elderly. We are doing this by improving the viscosity and stability of known biologics, for our own formulations as well as for those of other biopharmaceutical companies to make their medicines better tolerated by patients and more easily administered.
Jeffrey S. Hackman - Chief Executive Officer
Jeffrey S. Hackman is President and Chief Executive Officer (CEO) of ReForm Biologics. Prior to joining ReForm, Jeff was President of US Operations for EUSA, a global pharmaceutical company focused on oncology and rare diseases. Previously, he had been acting CEO of Novelion Therapeutics, where he transformed the company to profitability. He joined Novelion from Shire Inc., where he had been Senior VP and Head of US Internal Medicine / Oncology Franchise. Previously, he established the North American oncology commercial division for Baxalta, following several years leading US commercial operations for Sigma Tau. He has also held senior roles in several other pharmaceutical companies.
Neal I. Muni, MD, MSPH - Chief Operating Officer
Dr. Neal Muni is Executive Vice President and Chief Operating Officer (COO) of ReForm. Prior to joining ReForm, Dr. Muni most recently served as the CEO of Azurity Pharmaceuticals (formerly CutisPharma). During his tenure, Dr. Muni led the transformation of CutisPharma from pharmacy distribution into a fully integrated specialty pharma, leading the acquisition of Silvergate Pharmaceuticals as well as overseeing the FDA approval and launch of two pipeline drugs, FIRVANQ® for clostridium difficile colitis and Katerzia® for pediatric hypertension.
Prior to Azurity, Dr. Muni served as the Head of New Product Planning and Corporate Strategy at Sunovion Pharmaceuticals. Before that, Dr. Muni was an engagement manager at the healthcare investment bank Leerink Swann (now SVB Leerink). He was a Medical Officer in the Division of Cardiovascular Devices at the FDA before joining Leerink. Over the past 20 years, Dr. Muni has maintained staff appointments at Harvard Medical School and its teaching hospitals, including Brigham and Women’s Hospital, Dana Farber Cancer Institute, and Faulkner Hospital, as well as the Wyss Institute at Harvard University. He received his MD as well as MSPH from the Tulane School of Medicine, and a BA in Business Economics and B.Sc. in Biochemistry from Brown University.
Kevin P. Kavanaugh - Chief Financial Officer
Robert Mahoney, Ph.D. - Chief Scientific Officer
Dr. Mahoney has spent 25 years leading the development of disruptive new products and processes for industries including water treatment, oilfield technologies, pharmaceuticals, agriculture, and mineral processing. Before joining ReForm, he served as VP of R&D under David Soane at Soane Energy, leading to the successful deployment of an innovative self-suspending proppant technology. Prior to joining Dr. Soane, he was VP of R&D at Polymer Ventures, designing and commercializing many new specialty polymer products. Previously, Dr. Mahoney was responsible for development of next-generation performance additives at Nalco (now part of Ecolab), the global leader in water and process treatment chemicals. He received his Ph.D. in physical organic chemistry from the University of Colorado at Boulder and has authored numerous patents, publications, and presentations.
Sharon Webb, M.D., Ph.D., J.D. - VP of Intellectual Property
BOARD OF DIRECTORS
James Sherblom - Chairman
Dr. Jim Sherblom is an entrepreneur, social impact investor, spiritual seeker, and transcendentalist. Jim was a founder of the Massachusetts Biotechnology Council and served as its second President. As Senior Vice President and Chief Financial Officer of Genzyme Corporation Jim led their initial public offering and helped create many of the early biotechnology industry’s most innovative financing structures. As Chairman and CEO of Transgenic Sciences Inc. he led a ten-fold growth of this company over a period of five years. As founding Managing Partner of Seaflower Ventures Jim has been involved as a founder, early investor, board member, or board chair of over a dozen early stage biotechnology, life science, and social impact companies over the last three decades. Jim currently serves as the largest investor and CFO of GrainPro Inc. and also on the board of Connected Homecare Inc. Jim holds a BA from Yale, an MBA from Harvard, and Master of Divinity and Doctor of Ministry degrees from Andover Newton Theological School.
Jeffrey S. Hackman
Zach Jonasson, Ph.D. - Co-founder
Barbara K. Finck, MD
Dr. Finck is a board-certified rheumatologist with more than 25 years of preclinical and clinical drug development experience in academic and biopharmaceutical settings. Dr. Finck, whose drug development activities have spanned multiple therapeutic areas, started her pharmaceutical career at ALZA as medical director for early clinical development of Ditropan-XL®, to treat spasms of the bladder. She subsequently held senior level positions at a half-dozen innovative biopharmaceutical companies. At Immunex (later acquired by Amgen) she was lead medical director for the Phase III clinical development of Enbrel® in rheumatoid arthritis and juvenile idiopathic arthritis. At Eos Biotechnology, she was VP for Clinical Development. In addition, she was on the executive teams at PDL Biopharma (VP, Clinical Development), Osprey Pharmaceuticals USA, Inc. (Senior VP, Research and Development, and Chief Medical Officer), and NKT Therapeutics, Inc. (Chief Medical Officer). In her role as the Chief Medical Officer at Coherus, she was instrumental in the development and approval of UDENYCA®, a biosimilar pegfilgrastim.
V. Bryan Lawlis, Ph.D.
John Yee, MD, MPH
Dr. John Yee is currently Chief Medical Officer at Sobi North America. Prior to joining Sobi, he served as Senior Vice President, Medical Affairs at Flexion Therapeutics, Senior Vice President and Global Head of Medical Affairs at Vertex Pharmaceuticals and Vice President, Medical Affairs, Safety and Operations at Intarcia Therapeutics. From 2011 to 2016, Dr. Yee was at AstraZeneca Pharmaceuticals, where he served as Vice President, US Head Medical Officer and Vice President and Head of Medical Affairs for the US Diabetes franchise. Dr. Yee began his industry career at Genzyme Corporation in 2003 as Director, Global Medical Programs and later served in other leadership roles, including Vice President, Global Medical Affairs and Vice President, Global Head, Evidence-Based Medicine and Health Outcomes Research. Dr. Yee earned his MD at Harvard Medical School and graduated from the T.H. Chan School of Public Health at Harvard with an MPH in Health Care Management. He completed his pediatric residency and fellowship training at Boston Children’s Hospital. Prior to joining industry, John held leadership roles at Boston Children’s Hospital and was a faculty member at Harvard Medical School.
John M. Sorvillo Ph.D. - Chairman
John Carpenter Ph.D.
Alan Herman, Ph.D.
Dr. Herman has over 35 years of experience in the life sciences sector and expert in protein characterization. He was most recently Chief Scientific Officer at Coherus Biosciences, a leading biopharmaceutical company developing safe, high-quality biosimilar therapeutics. Previously, he was Vice President of Product Development and CSO at Althea Technologies and President of WindRose Analytica, Inc. Dr. Herman worked a number of other biotech companies, including Genentech and Amgen. He has a Ph.D. in Protein Chemistry from Duke University.
Andrew Jones, D. Phil.
Mark Moody, Ph.D.
Neil Schauer, Ph.D.
Ms Szela has an M.B.A. from the University of Illinois at Chicago, US, and a B.S. Nursing degree from the University of Illinois at Chicago, US.